Navigation Links
FDA Approves IXEMPRA(TM) (ixabepilone), a Semi-Synthetic Analog of Epothilone B, for the Treatment of Advanced Breast Cancer
Date:10/16/2007

iscontinuation of IXEMPRA should be considered in patients who develop cardiac ischemia or impaired cardiac function due to reports of cardiovascular adverse reactions (e.g., myocardial ischemia, superventricular arrhythmia, and ventricular dysfunction). The frequency of cardiac adverse reactions (myocardial ischemia and ventricular dysfunction) was higher in the IXEMPRA in combination with capecitabine (1.9%) than in the capecitabine alone (0.3%) treatment group.

POTENTIAL FOR COGNITIVE IMPAIRMENT FROM EXCIPIENTS

IXEMPRA contains dehydrated alcohol USP. Consideration should be given to the possibility of central nervous system and other effects of alcohol.

ADVERSE REACTIONS

The most common adverse reactions (greater than or equal to 20%) reported by patients receiving IXEMPRA were peripheral sensory neuropathy, fatigue/asthenia, myalgia/arthralgia, alopecia, nausea, vomiting, stomatitis/mucositis, diarrhea, and musculoskeletal pain. The following additional events occurred in greater than or equal to 20% in combination treatment: palmar-plantar erythrodysesthesia (hand-foot) syndrome, anorexia, abdominal pain, nail disorder, and constipation. Drug-associated hematologic abnormalities (>40%) include neutropenia, leukopenia, anemia, and thrombocytopenia.

About Bristol-Myers Squibb

For more than 40 years, Bristol-Myers Squibb has been committed to building a unified vision for the future of cancer treatment. With expertise, dedication and resolve, that vision led to the development of a diverse global portfolio of anti-cancer therapies that are an important cornerstone of care today. Hundreds of scientists in Bristol-Myers Squibb's Research & Development organization are studying ways to improve current cancer treatments and identify better, more effective medicines for the future. Bristol-Myers Squibb is a global pharmaceutical and related health care products company whose mission is to extend and enhance human life.

For mor
'/>"/>

SOURCE Bristol-Myers Squibb Company
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. UW-Madison approves new research institute
2. FDA approves GEs heart-imaging technology
3. Senate approves bill to expand stem cell funding
4. FDA approves advanced digital mammography system
5. Building commission approves Institutes for Discovery
6. UW Board of Regents approves $134 million medical research facility
7. FDA approves Bone Cares Hectorol for treatment of kidney disease
8. Analog people in the Digital Revolution, part II
9. Analog people in the digital revolution
10. Unique Surface Treatment of Novel TSK-GEL ODS Columns Provide Separation of Aqueous and Fat Soluble Vitamins
11. Improve Recovery and Reproducibility with Pre-Treatment of Analytical TSK-GEL G3000SWXL Size Exclusion Columns
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/30/2015)... & Budapest, Hungary (PRWEB) April 30, 2015 ... web-based electronic lab notebook with integrated protocols and ... providing chemistry software solutions and consulting services for ... to the development of Labguru’s newest feature: chemical ... of deep domain features for biologists, bio-chemists, and ...
(Date:4/30/2015)... 2015 WuXi PharmaTech (Cayman) Inc. ("WuXi" or ... contract R&D services provider, today announced that its board ... dated April 29, 2015, from a consortium (the "Consortium") ... founder, chairman and chief executive officer of the Company, ... a transaction (the "Transaction") involving the acquisition of all ...
(Date:4/30/2015)... Sterlitech is proud to offer ... PX, PY, and PZ Polyacrylonotrile (PAN) membranes , ... Designed to be ideal for oil removal in ... critical process requirements where the presence of oils ... regulations on industrial wastewater discharge and quality requirements ...
(Date:4/29/2015)... N.J. , April 29, 2015 Cambrex Corporation ... results will be released on Friday, May 1, 2015 before ... The Company will host a conference call to ... When: , Friday, May 1, ... , 1-888-468-2440 for U.S.1-719-325-2454 for International  Passcode:  7993632 ...
Breaking Biology Technology:Labguru Integrates ChemAxon's Marvin JS, to Enhance Functionality for Chemists 2WuXi PharmaTech Announces Receipt of Proposal 2WuXi PharmaTech Announces Receipt of Proposal 3WuXi PharmaTech Announces Receipt of Proposal 4WuXi PharmaTech Announces Receipt of Proposal 5WuXi PharmaTech Announces Receipt of Proposal 6Sterlitech Offers New Ultrafiltration Membranes 2
... INDIANAPOLIS, Oct. 30, 2009 Amylin Pharmaceuticals, Inc., (Nasdaq: ... ) today announced that the U.S. Food and Drug Administration ... BYETTA is now approved for use as a stand-alone medication ... in adults with type 2 diabetes. Previously, it was approved ...
... Calif., Oct. 30 ThermoGenesis Corp. (Nasdaq: ... and store adult stem cells, announced today it will report ... 2009, on Thursday, November 5, 2009. , ... host a conference call Thursday, November 5, 2009 at 2:00 ...
... , ROCKVILLE, Md., Oct 30 Novavax, Inc. (Nasdaq: ... third quarter financial results in a press release to be ... 2009. The Company will hold an investor conference call to ... Friday, November 6, 2009. The call will be hosted by ...
Cached Biology Technology:BYETTA Approved for Expanded Use as First-Line Treatment for Type 2 Diabetes 2BYETTA Approved for Expanded Use as First-Line Treatment for Type 2 Diabetes 3BYETTA Approved for Expanded Use as First-Line Treatment for Type 2 Diabetes 4BYETTA Approved for Expanded Use as First-Line Treatment for Type 2 Diabetes 5BYETTA Approved for Expanded Use as First-Line Treatment for Type 2 Diabetes 6BYETTA Approved for Expanded Use as First-Line Treatment for Type 2 Diabetes 7Thermogenesis Corp. to Announce First Quarter Fiscal 2010 Results on November 5, 2009 2Novavax Announces Release Date of 2009 Third Quarter Financial Results and Investor Conference Call 2
(Date:4/10/2015)... April 10, 2015 Research and ... the "Security Competitive Profiles - NEC" report ... NEC will continue to supply a range ... market, with a company focus on the development of ... Winning opportunities in the Asia-Pacific ...
(Date:4/8/2015)... April 8, 2015  Infinisource, a leading provider ... and Morpho, a leading supplier of biometric identification ... the market,s most advanced biometrically-enabled time clock, the ... time clock is setting a bold, new standard ... for the small and mid-size employer. When connected ...
(Date:4/2/2015)... HAMBURG, Germany , April 2, 2015 /PRNewswire/ ... ten fingerprint tests DERMALOG by far outperforms the ... While always maintaining high accuracy, the system is ... second. Hence, the speed proves up to be ... 40% faster than its runner-up performance. ...
Breaking Biology News(10 mins):NEC Security Competitive Profile 2015 2iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 2iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 3DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 2DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 3
... The first real-world, demonstration-scale project in Nevada for ... stage of research at the University of Nevada, Reno. ... is an economical, commercially viable renewable energy source in ... outdoor cold-weather crop of algae as part of their ...
... TGen Clinical Research Services (TCRS) at Scottsdale Healthcare ... may offer broad potential to treat solid tumors. ... conducted at TGen Clinical Research Services at Scottsdale Healthcare, ... (TGen) and Scottsdale-based Scottsdale Healthcare Corp., and at Mayo ...
... bleaching is not only a con, but is dangerous to ... journal. The light treatment gives absolutely no benefit over ... four times as much as sunbathing, reports a study in ... match Tom Cruise,s glittering pearly-whites would be better off ignoring ...
Cached Biology News:Success for first outdoor, large-scale algae-to-biofuel research project in Nevada 2TGen Clinical Research Services at Scottsdale Healthcare and Mayo Clinic study new cancer drug 2
... Continuing a tradition of progressive centrifuge design ... series. The Centra-CL3 and Centra-CL3R (refrigerated) general ... laboratory., Quality Control Over Sample Preparation ... lock up to 99 protocols and has ...
... Molecular Probes intensely fluorescent and ... potential for use in a variety ... deliver a strong signal. Unfortunately, protein- ... regions that may cause them to ...
... Centra-CL5R multi-purpose centrifuge offers both high-speed ... assortment of rotor options, making it ... applications., Maximum Versatility , High-speed ... angle rotors or high-volume (4 x 250mL) ...
... licensed, high throughput, water bath thermal cycler capable ... microplates. This equates to 9,216 reactions per run ... rapidly transfers a basket of plates between three ... are considerably faster than those of peltier block ...
Biology Products: